Drugs /

ningetinib

Back to Drugs List

Overview

NCI Definition [1]:
The tosylate salt form of ningetinib, an orally available inhibitor of the receptor tyrosine kinases c-MET/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor 2 (VEGFR2 KDR), Axl (UFO), Mer, and Fms-like tyrosine kinase 3 (Flt3; CD135; STK1; FLK2), with antineoplastic activity. Upon administration, ningetinib binds to a variety of kinases, including c-Met, VEGFR2, Axl, Mer and Flt3, thereby inhibiting their signaling pathways. This inhibits growth, angiogenesis and metastasis of tumor cells that overexpress these kinases. c-Met, VEGFR2, Axl, Mer and Flt3 are overexpressed by many tumor cell types and play key roles in tumor cell proliferation, survival, invasion and metastasis.

Clinical Trials

View Clinical Trials for ningetinib

Ningetinib has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating ningetinib, 1 is phase 1 (0 open).

FLT3 Mutation is the most frequent biomarker inclusion criterion for ningetinib clinical trials.

Acute myeloid leukemia is the most common disease being investigated in ningetinib clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ningetinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ningetinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ningetinib tosylate, ct-053 tosylate, ct-053ptsa, ct-053-ptsa, ct053ptsa, ningetinib tosylate
Drug Target(s) [2]:
AXL, FLT3, MET
NCIT ID [1]:
C148529

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.